Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-Strong (also known as M STRONG OD CAP) is an oral nutritional supplement and generic small molecule formulation developed and marketed by the Indian pharmaceutical company Lloyd Healthcare. It contains a combination of alpha lipoic acid (100 mg) and folic acid (1.5 mg). Alpha lipoic acid serves as a potent antioxidant and a vital cofactor for mitochondrial enzymes like pyruvate dehydrogenase, aiding in metabolic health and the management of diabetic neuropathy. Folic acid acts as a precursor for tetrahydrofolate, which is essential for DNA synthesis and the regulation of homocysteine levels. The product is specifically indicated for patients with cardiovascular disease and diabetes-related complications to support nerve function and vascular health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on M-Strong.